• SP600125: Reliable JNK Inhibition in Cell Assays

  2026-09-16

  This scenario-based guide explains how SP600125 (SKU A4604) can improve the interpretation and reproducibility of cell viability, proliferation, apoptosis, and inflammation experiments. It covers mechanism, solvent compatibility, dose selection, data interpretation, and practical supplier-selection criteria.

• Tubastatin A: From HDAC6 Mechanism to Translation

  2026-09-16

  Tubastatin A is more than a selective HDAC6 inhibitor: it is a mechanistic probe for connecting cytoskeletal regulation, inflammatory signaling, and regulated cell death. This thought-leadership analysis interprets recent porcine cardiac-arrest data and translates the findings into practical strategies for cancer biology, inflammation, neuroprotection, and translational assay design.

• WQ-C-401 Targets PDGFR in Experimental PAH

  2026-09-15

  The reference study identifies WQ-C-401 as a selective PDGFR inhibitor that suppresses PDGF-driven signaling, pulmonary vascular remodeling, and right-heart stress in monocrotaline-induced pulmonary arterial hypertension. Its combination of kinome profiling, cellular assays, and in vivo pathology provides a useful framework for evaluating PDGFR-directed therapies beyond pressure reduction alone.

• BFH772 (VEGFR2 inhibitor): Workflow Guide

  2026-09-15

  BFH772 is a selective small-molecule VEGFR2 inhibitor for kinase, cellular, and angiogenesis studies that require an organic-solvent-compatible compound. Its water insolubility, storage constraints, and absence of directly matched paper evidence require fresh solution preparation, vehicle controls, and independent assay validation; it is not appropriate for protocols that require a water-soluble reagent or broad-spectrum kinase inhibition.

• SFRP1, Wnt/β-Catenin, and Oral Fibrosis

  2026-09-14

  A 2024 study links reduced SFRP1 with neutrophil infiltration, collagen accumulation, and Wnt/β-catenin activation in arecoline-induced oral submucous fibrosis. Its combination of tissue correlation, SFRP1 overexpression, and pathway-activation reversal experiments provides a useful mechanistic framework for studying inflammatory fibrosis in oral disease.

• RRP Restores Lipid Metabolism in HIRI

  2026-09-14

  This Journal of Ethnopharmacology study identifies restoration of hepatocyte cholesterol handling as a central mechanism by which Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury. Using mouse HIRI models, oleate–palmitate-loaded hepatocytes, transcriptomics, and pathway-directed inhibition, the authors connect AMPK activation with reduced SCAP-SREBP2 cholesterol synthesis and enhanced LXRα-dependent cholesterol efflux.

• 17-AAG (Tanespimycin) Cancer Research Workflow

  2026-09-13

  17-AAG (Tanespimycin) provides a practical route to connect HSP90 client-protein loss with viability, apoptosis, and pathway-level readouts across cancer models. This workflow also shows how findings on regulated protein secretion can improve assay controls without overstating an unvalidated antiviral application.

• Catharanthus ‘Timebomb’ Defense Against Herbivores

  2026-09-12

  The reference study shows how Catharanthus roseus combines spatially separated alkaloid precursors with HIVE-dependent transcriptional reprogramming to defend against chewing herbivores while reallocating resources during cold stress. Its integrated insect bioassays, transcriptomic analyses, promoter assays, and protein–protein interaction studies provide a mechanistic framework for inducible chemical defense and stress prioritization.

• Telmisartan and the Next Era of Cardiac Hypertrophy

  2026-09-11

  Telmisartan is more than an angiotensin II receptor antagonist: it is a strategic upstream perturbation for dissecting how AT1R signaling connects with maladaptive remodeling. This thought-leadership guide integrates Telmisartan with emerging RIP3/CaMKII biology to help translational researchers design more informative cardiac hypertrophy studies.

• SmCPK20–SmWRKY2 Control of Tanshinone Synthesis

  2026-09-11

  The reference study identifies a post-translational mechanism connecting jasmonate perception, calcium-dependent protein kinase activity, and tanshinone biosynthesis in Salvia miltiorrhiza. Its central finding is that SmCPK20 phosphorylates SmWRKY2 at Thr-256, strengthening SmWRKY2 activation of SmCPS1 after jasmonate-induced release from SmJAZ3 repression.

• CHIR 99021 Trihydrochloride for Organoids

  2026-09-10

  Use CHIR 99021 trihydrochloride as a tunable GSK-3 inhibitor for organoid expansion, stem cell maintenance and differentiation, and metabolic assay design. This guide connects concentration screening, organoid engineering, and glucose-related applications while separating product-backed parameters from workflow starting points.

• α2-adrenergic receptor agonist Workflows

  2026-09-10

  Build reproducible α2-adrenergic receptor signaling assays with a DMSO-soluble small molecule suited to receptor pharmacology, immune profiling, and hydrogel-based osteosarcoma recurrence research. The workflow separates direct tumor-cell effects from immune-mediated responses and includes practical controls for solubility, stability, timing, and formulation quality.

• Letrozole: From Aromatase Biology to Assay Design

  2026-09-09

  Letrozole is a non-steroidal aromatase inhibitor whose value in research extends beyond simple enzyme blockade. This article connects aromatase mechanism, endocrine biomarker logic, and cross-domain assay design while clarifying how clinical endocrine-therapy evidence can guide experimental decisions.

• How p38α Conformation Drives Dephosphorylation

  2026-09-09

  The reference study shows that some ATP-site kinase inhibitors do more than block p38α catalytic activity: they reshape the activation loop so WIP1 can dephosphorylate it more efficiently. Biochemical and X-ray structural evidence establishes a dual-action mechanism that may guide more selective strategies for controlling kinase signaling.

• Y-27632: Selective ROCK Inhibitor Guide

  2026-09-08

  Y-27632 is a selective ROCK inhibitor that targets ROCK1 and ROCK2 through reversible, ATP-competitive binding. Its strongest research uses include cell stress fiber disruption, cytoskeletal dynamics modulation, and controlled ROCK signaling pathway research, while tissue-engineering evidence supports further mechanistic study rather than clinical use.

8109 records 1/541 page Next 12345 下5页 Last page